Starpharma has signed a Research Agreement with MSD, the tradename of Merck & Co., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma's proprietary DEP® technology. 

Dr Jackie Fairley, CEO of Starpharma commented: "MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area."

DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. DEP® ADCs are the subject of internal and partnered programs.

Starpharma has previously demonstrated the significant advantages conveyed by DEP® ADCs in multiple preclinical studies, including its DEP® HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcyla in a human ovarian cancer model. Starpharma's DEP® technology has already yielded four clinical stage oncology products, including one under development by AstraZeneca.